Key result
NLRP3/AIM2-IN-3 attenuates post-MI left atrial remodeling and improves survival in frail mice by blocking pyroptosis.
Why the study?
Frailty has been linked to adverse cardiovascular outcomes after myocardial infarction, but its mechanistic contribution to left atrial remodeling and dysfunction remains poorly defined.
Does NLRP3/AIM2-IN-3 attenuate left atrial remodeling and dysfunction in frail aged mice after myocardial infarction?
Does NLRP3/AIM2-IN-3 attenuate left atrial remodeling and dysfunction in frail aged mice after myocardial infarction?
Frailty exacerbates post-MI left atrial remodeling in aged mice via inflammasome-mediated pyroptosis, which can be attenuated by dual NLRP3/AIM2 inhibition.
Frailty may worsen post-MI atrial outcomes via pyroptosis in aged models; leaves open whether NLRP3/AIM2 inhibition benefits frail patients.
Myocardial infarction (MI) is a major driver of left atrial dysfunction and structural remodeling, substantially increasing the risks of heart failure and stroke. Frailty, a common geriatric syndrome, has been linked to adverse cardiovascular outcomes, but its mechanistic contribution remains poorly defined. This study examined the impact of frailty on left atrial remodeling after MI in aged mice and explored the underlying mechanisms. Frailty was modeled in 24-month-old IL-10 knockout mice, and MI was induced by permanent ligation of the left anterior descending coronary artery. Cardiac structure and function were evaluated by echocardiography and histological analysis. In vitro, frailty enhances the susceptibility of atrial cardiomyocytes to pathological remodeling under combined senescent and ischemic stress. RNA-seq of left atrial tissue from wild-type and frail mice after MI was performed, and key findings were validated by quantitative real-time polymerase chain reaction, Western blotting, and immunofluorescence. Although frailty had no baseline effect on left atrial structure or function, frail mice developed pronounced left atrial dilation, increased fibrosis and inflammation, and reduced survival 28 days after MI. Transcriptomic analysis showed enrichment of pyroptosis-, immune activation-, and cytokine signaling-related pathways, with robust activation of NLR and AIM2 inflammasomes. Pharmacological inhibition with the dual NLRP3 and AIM2 inflammasome inhibitor NLRP3/AIM2-IN-3 attenuated cardiomyocyte pyroptosis, reduced myocardial inflammation and pathological remodeling, and improved left atrial function. These findings demonstrate that frailty exacerbates post-MI left atrial remodeling and dysfunction in aged mice by promoting inflammasome-mediated pyroptosis and identify NLRP3/AIM2-IN-3 as a promising therapeutic strategy for frailty-associated left atrial injury.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied Myocardial infarction and frailty. Frailty (IL-10 knockout model) vs. Wild-type mice was evaluated on Left atrial remodeling, dysfunction, and survival. Frailty exacerbated post-MI left atrial remodeling and reduced survival at 28 days in aged mice by promoting inflammasome-mediated pyroptosis, which was attenuated by NLRP3/AIM2-IN-3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: